The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 23990933.
- Also identified by DOI 10.1371/journal.pone.0071140 and PMC identifier 3747201.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
To investigate the association of SOX2 expression in tumor with clinicopathological features and survival of non-small-cell lung carcinoma (NSCLC) patients. Publications assessing the clinicopathological characteristics and prognostic significance of SOX2 in NSCLC were identified up to May 2013. A meta-analysis of eligible studies was performed using standard statistical methods to clarify the association between SOX2 expression and these clinical parameters. A total of eight studies met the inclusion criteria. Analysis of these data showed that SOX2 expression was positively associated with squamous histology, (pooled OR = 5.26, 95% CI: 1.08-25.6, P = 0.040). Simultaneously, we also found that SOX2 expression was positively associated with overall survival (pooled HR = 0.65, 95% CI: 0.47-0.89, P = 0.007, random-effect). SOX2 expression in tumor is a candidate positive prognostic biomarker for NSCLC patients.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Gene Expression Regulation, Neoplastic
- Lung Neoplasms
- SOXB1 Transcription Factors